- Monitoring the dynamics of clinical and laboratory markers of chronic heart failure during 12 months of sacubitril/valsartan treatment2021 | First Faculty of Medicine
- Sacubitril/valsartan - new dual inhibitor of neprilysin and angiotensin II receptors2016 | First Faculty of Medicine
- Přínos zahájení léčby sacubitril-valsartanem u pacientů s akutní dekompenzací srdečního selhání se sníženou ejekční frakcí2020 | First Faculty of Medicine
- Sacubitril/valsartan in the treatment of chronic heart failure2016 | First Faculty of Medicine
- Quality of life and sacubitril/valsartan2019 | First Faculty of Medicine
- A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction2020 | First Faculty of Medicine
- Sacubitril/valsartan in the treatment of heart failure with severe left ventricular systolic dysfunction2021 | First Faculty of Medicine
- What does the fixed combination of valsartan and sacubitrilu patients with heart failure - the results of the study PARADIGM-HF2017 | Faculty of Medicine in Hradec Králové
- Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan2018 | First Faculty of Medicine
- Sacubitril-valsartan in the treatment of chronic heart failure with decreased left ventricular ejection fraction2017 | First Faculty of Medicine
- Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study2020 | First Faculty of Medicine
- Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontanenously Hypertensive Rats: Different Interaction with the Renin-Angiotensin-Aldosterone System2022 | Faculty of Medicine in Hradec Králové
- Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study2019 | First Faculty of Medicine
- Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure2023 | First Faculty of Medicine
- Transition from angiotensin-converting enzyme inhibitor/angiotensin-II-receptor-blocker to sacubitril/valsartan in chronic heart failure patients: Initial experiences in clinical practice2018 | Central Library of Charles University, Third Faculty of Medicine
- Co je nového v diagnostice a léčbě srdečního selhání na začátku roku 2021?2021 | First Faculty of Medicine
- Oversights and mistakes in heart failure therapy with left ventricular dysfunction2018 | First Faculty of Medicine
- PARAGON-HF study (Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction)2020 | First Faculty of Medicine
- Pharmacological therapy for chronic heart failure2018 | First Faculty of Medicine
- New concept in the treatment of cardiovascular diseases - dual inhibition of neutral endopeptidase and RAA system2017 | First Faculty of Medicine
- 2021 ACC update of the heart failure guidelines2021 | First Faculty of Medicine
- What's new in the diagnosis and treatment of heart failure2016 | First Faculty of Medicine
- Pharmacotherapy of chronic heart failure in senescence2023 | Faculty of Medicine in Hradec Králové
- Význam maximalizované farmakoterapie srdečního selhání se sníženou systolickou funkcí2020 | First Faculty of Medicine
- Drug induced angioedema2023 | Faculty of Medicine in Hradec Králové
- Geographic variations in the PARADIGM-HF heart failure trial2016 | First Faculty of Medicine
- Studie PARADIGM-HF - Změna paradigmatu v léčbě chronického srdečního selhání?2015 | First Faculty of Medicine
- Global Differences in Heart Failure With Preserved Ejection Fraction : The PARAGON-HF Trial2021 | First Faculty of Medicine
- Management of patients with chronic heart failure2021 | First Faculty of Medicine
- Renin-Angiotensin-Aldosterone System: Friend or Foe-The Matter of Balance. Insight on History, Therapeutic Implications and COVID-19 Interactions2021 | Faculty of Medicine in Hradec Králové